Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ESSA Pharma's Enterprise Value is $-100.10 Mil.
ESSA Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was $-20.89 Mil. Therefore, ESSA Pharma's EV-to-FCF for today is 4.79.
The historical rank and industry rank for ESSA Pharma's EV-to-FCF or its related term are showing as below:
EPIX's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 17.905 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ESSA Pharma's PE Ratio (TTM) for today is calculated as:
ESSA Pharma's share price for today is $0.2012.
ESSA Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ESSA Pharma EV-to-FCF Related Terms
ESSA Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ESSA Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ESSA Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ESSA Pharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ESSA Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ESSA Pharma's EV-to-FCF falls into.
ESSA Pharma's current Enterprise Value is $-100.10 Mil.
ESSA Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESSA Pharma (EPIX) has a EV-to-FCF of 4.79 as of Aug. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ESSA Pharma and its competitors.
Is ESSA Pharma's EV-to-FCF too high?
ESSA Pharma's current EV-to-FCF is 4.79. The Biotechnology industry median EV-to-FCF is 17.91. ESSA Pharma's value of 4.79 is 73.2% below this industry median. Overall, ESSA Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does ESSA Pharma's EV-to-FCF compare to SLXN and NLSP?
ESSA Pharma's EV-to-FCF of 4.79 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 17.91. ESSA Pharma's value of 4.79 is 73.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.91, based on 320 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ESSA Pharma's current EV-to-FCF of 4.79 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ESSA Pharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ESSA Pharma's current EV-to-FCF is 4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ESSA Pharma stock overvalued right now?
ESSA Pharma (EPIX) has a current EV-to-FCF of 4.79. The current EV-to-FCF is 4.79 and 73.2% below the Biotechnology industry median of 17.91. ESSA Pharma's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ESSA Pharma (EPIX), the current EV-to-FCF is 4.79 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
22GF Score
Get the complete analysis for EPIX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPIX has been successfully added to your 
